Annovis Bio Inc. (ANVS): Price and Financial Metrics
ANVS Price/Volume Stats
| Current price | $8.01 | 52-week high | $22.49 |
| Prev. close | $8.47 | 52-week low | $4.53 |
| Day low | $7.94 | Volume | 160,299 |
| Day high | $8.60 | Avg. volume | 891,394 |
| 50-day MA | $9.73 | Dividend yield | N/A |
| 200-day MA | $9.76 | Market Cap | 89.48M |
ANVS Stock Price Chart Interactive Chart >
Annovis Bio Inc. (ANVS) Company Bio
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Latest ANVS News From Around the Web
Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
Annovis Bio to Participate in the 139th Yale CEO SummitBERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023. The Yale CEO Summit is a bi-annual event; it brings together influential CEOs from major US Fortune 500 companies for informal ye |
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s DiseaseBERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024. "We are pleased to share the completion of our Parkinson's study which marks a significant step forward in our ongoing mission t |
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's WhyAnnovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease. |
Annovis Bio Appoints Andrew Walsh as Vice President FinanceBERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer’s and Parkinson’s clinical trials in 2024. The addition of Andrew Walsh to our |
ANVS Price Returns
| 1-mo | 3.22% |
| 3-mo | 36.92% |
| 6-mo | -11.88% |
| 1-year | -26.65% |
| 3-year | -74.31% |
| 5-year | N/A |
| YTD | -57.17% |
| 2023 | 39.24% |
| 2022 | -23.61% |
| 2021 | 133.16% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...